Achieving optimal lipid values in patients with dyslipidemia is associated with reduced risk of cardiovascular events

Charland, Scott L.; Cziraky, Mark J.; Quimbo, Ralph; Karas, Richard H.; Insull, William; Davidson, Michael; Stanek, Eric J.

doi:10.1016/j.jacl.2008.06.009

Cited by 8 publications

(12 citation statements)

References 31 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…78 These data emphasize the importance of achieving OLVs for all 3 lipid parameters (LDL-C, HDL-C, and TG) to maximize the reduction in cardiovascular events. 78 In a similar study, evaluating the risk of cardiovascular events, a retrospective cohort analysis was conducted using a 1.1-millionmember managed care database. 79 In this analysis, the risk of experiencing cardiovascular events was compared between patients who attained combined OLVs (LDL-C, HDL-C, and TG) and patients who did not attain the OLVs.…”

Section: ■■ Summarymentioning

confidence: 90%

“…The analyses revealed that there was a difference in cardiovascular event-free survival between patients who achieved optimal lipid values (OLVs) for LDL-C and those who did not (hazard ratio [HR] = 0.75; P < 0.001) in patient cohort 1. 78 For patients in cohort 2, there was a large difference in cardiovascular event-free survival in patients who achieved OLVs for 2 lipid parameters (LDL-C and HDL-C or TG) versus those patients who did not (HR = 0.54; P < 0.001). 78 Patients in cohort 3 who achieved OLVs for all 3 lipid parameters (LDL-C, HDL-C, and TG), compared with those who did not (HR = 0.54; P = 0.001), showed the most striking difference in cardiovascular event-free survival.…”

Section: ■■ Summarymentioning

confidence: 91%

“…78 For patients in cohort 2, there was a large difference in cardiovascular event-free survival in patients who achieved OLVs for 2 lipid parameters (LDL-C and HDL-C or TG) versus those patients who did not (HR = 0.54; P < 0.001). 78 Patients in cohort 3 who achieved OLVs for all 3 lipid parameters (LDL-C, HDL-C, and TG), compared with those who did not (HR = 0.54; P = 0.001), showed the most striking difference in cardiovascular event-free survival. 78 These data emphasize the importance of achieving OLVs for all 3 lipid parameters (LDL-C, HDL-C, and TG) to maximize the reduction in cardiovascular events.…”

Section: ■■ Summarymentioning

confidence: 91%

“…78 Patients in cohort 3 who achieved OLVs for all 3 lipid parameters (LDL-C, HDL-C, and TG), compared with those who did not (HR = 0.54; P = 0.001), showed the most striking difference in cardiovascular event-free survival. 78 These data emphasize the importance of achieving OLVs for all 3 lipid parameters (LDL-C, HDL-C, and TG) to maximize the reduction in cardiovascular events. 78 In a similar study, evaluating the risk of cardiovascular events, a retrospective cohort analysis was conducted using a 1.1-millionmember managed care database.…”

Section: ■■ Summarymentioning

confidence: 92%

“…To address the percentage of patients who fail to achieve lipid goals, as well as the potential outcomes from this failure, longitudinal, retrospective analyses of administrative claims data and laboratory results from a U.S. managed care organization were performed in 3 patient cohorts. 78 In cohort 1, LDL-C was not optimal at baseline. In cohort 2, LDL-C plus HDL-C or TG were not optimal at baseline.…”

Section: ■■ Summarymentioning

confidence: 97%

See 4 more Smart Citations

Targeting Low HDL-Cholesterol to Decrease Residual Cardiovascular Risk in the Managed Care Setting

Cziraky

Watson

Talbert³

2008

JMCP

Self Cite

View full text Add to dashboard Cite

Section: ■■ Summarymentioning

confidence: 90%

Section: ■■ Summarymentioning

confidence: 91%

Section: ■■ Summarymentioning

confidence: 91%

Section: ■■ Summarymentioning

confidence: 92%

Section: ■■ Summarymentioning

confidence: 97%

See 3 more Smart Citations

Targeting Low HDL-Cholesterol to Decrease Residual Cardiovascular Risk in the Managed Care Setting

Cziraky

Watson

Talbert³

2008

JMCP

Self Cite

View full text Add to dashboard Cite

Biomarkers of Exposure and Biomarkers of Potential Harm in Adult Smokers Who Switch to e-Vapor Products Relative to Cigarette Smoking in a 24-week, Randomized, Clinical Trial

Edmiston

Webb

Wang

et al. 2022

Nicotine &Amp; Tobacco Research

View full text Add to dashboard Cite

Introduction Long-term health effects of e-vapor products (EVPs) are not well-established. We compared biomarkers of exposure (BoE) to select harmful and potentially harmful constituents (HPHCs) and biomarkers of potential harm (BoPH) in adult smokers (AS) who switched to EVPs vs continued smoking for 24 weeks. Methods AS (n=450, >10 cigarettes per day [CPD] for ≥10 years), were randomly assigned to continue smoking (Control) or switch to one of two cartridge-based EVPs (Test 1 - classic; Test 2 - menthol, 4% nicotine). BoE and BoPH were measured at baseline and 12 Weeks. A subset of 150 Control and EVP subjects (switchers with eCO ≤8 ppm and <10% baseline CPD) were followed to 24 weeks, the focus of this manuscript. Results Total NNAL and carboxyhemoglobin (COHb) were significantly reduced (p<0.0001) in Test 1 and Test 2 at 24 weeks. Urinary nicotine equivalents (NE) were not statistically significantly different between the Control and EVP groups. At Week 24, statistically significant reductions (p<0.05) were observed for white blood cell counts, 11-dehydrothromboxane β2, and sICAM in both test groups, and there were several significant changes in measures of pulmonary function. High-density lipoprotein-cholesterol (HDL-C) and 8-epi-prostaglandin-F2α were directionally favorable in both EVP groups vs Control. Conclusions We demonstrate that significant reductions of selected HPHCs in EVP aerosol results in significant reductions in BoEs and favorable changes in BoPHs after switching to EVPs for 24 weeks. These changes approached those reported for smoking cessation, suggesting that switching to exclusive use of the EVPs may be less harmful than continuing smoking. Implications Cigarette smoking causes serious diseases. Switching from cigarettes to a noncombustible product is a potential harm reduction pathway for AS unable or unwilling to quit. Long-term health effects of EVPs compared to continued smoking have not been extensively studied. We present BoE evidence on select HPHCs and BoPHs related to inflammation and oxidative stress in AS completely switching to two EVPs. This study demonstrates significant reductions in BoEs (except for nicotine) accompanied with favorable changes in various BoPHs, including pulmonary function. The totality of evidence suggests that exclusive EVP use may present lower health risks compared to smoking cigarettes.

show abstract

Impact of optimal lipid value achievement between 2005 and 2009 in patients with mixed dyslipidaemia on cardiovascular event rates

Cziraky

Tan

Bullano

et al. 2011

International Journal of Clinical Practice

View full text Add to dashboard Cite

show abstract

Achieving optimal lipid values in patients with dyslipidemia is associated with reduced risk of cardiovascular events

Cited by 8 publications

References 31 publications

Targeting Low HDL-Cholesterol to Decrease Residual Cardiovascular Risk in the Managed Care Setting

Targeting Low HDL-Cholesterol to Decrease Residual Cardiovascular Risk in the Managed Care Setting

Biomarkers of Exposure and Biomarkers of Potential Harm in Adult Smokers Who Switch to e-Vapor Products Relative to Cigarette Smoking in a 24-week, Randomized, Clinical Trial

Impact of optimal lipid value achievement between 2005 and 2009 in patients with mixed dyslipidaemia on cardiovascular event rates

Contact Info

Product

Resources

About